Search
mogamulizumab-kpkc (Poteligeo)
Indications:
- treatment of relapsed or refractory mycosis fungoides or Sezary syndrome after 1 prior systemic therapy
Dosage:
- 4 mg/mL 5 mL (injection)
Adverse effects:
common
- rash, infusion-related reactions, fatigue, diarrhea, musculoskeletal pain, upper respiratory tract infection.
serious
- dermatologic toxicity, infusion reactions, infections, autoimmune disorders
- complications of allogeneic stem cell transplantation after treatment with the drug
Mechanism of action:
- monoclonal Ab that binds to CC chemokine receptor-4 (CCR4)
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- RxNorm
- FDA News Release. Aug 8, 2018
FDA approves treatment for two rare types of non-Hodgkin lymphoma.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm616176.htm